Leading CDMO selected amongst hundreds of worldwide nominations by Biotech Breakthrough Awards
BALTIMORE (November 6, 2025) — Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, was named this year’s winner of the Biotech Breakthrough Awards’ Overall Biotech Company of the Year award. The honor recognized Bora’s recent growth and its unique ability to provide the hands-on reliability of a dedicated partner with the infrastructure and scale of a global leader.
After a period of steady expansion, 2025 was another pivotal year for Bora’s growth and industry leadership. In July, the Company expanded its Canadian facility with the addition of advanced filling technology, increasing annual production capacity to more than 50 million units. Shortly after, Bora unveiled a multi-year development plan for its Maple Grove, Minnesota site, including the build-out of 100,000 square feet of new manufacturing space. These strategic investments further increase capacity while positioning Bora to meet rising demand across a growing range of drug programs.
“We’re proud that the Biotech Breakthrough Awards have recognized our team’s industry-leading work,” said J.D. Mowery, president of Bora’s CDMO business. “Our core philosophies are built on trust, communication, and service – key tenets that this award recognizes. The partnerships we’ve built are transforming patients’ health every day, and the world class talent at Bora will continue to strengthen them while expanding our future production capacity.”
Bora’s CDMO division specializes in complex oral solid dose, liquid, semi-solid, and sterile injectable products with fill-finish capabilities. Its collaborations include some of the top 100 pharmaceutical companies, making Bora a trusted partner for the therapies shaping the future of medicine.
The company’s flexible platforms, integrated capabilities, and regulatory expertise remove variables that commonly derail production, resulting in an unmatched on-time, in-full (OTIF) delivery record. Bora’s service sets a new standard for reliability that both partners and patients depend on.
Bora is a global CDMO operating seven state-of-the-art facilities across North America and Asia. From early development and scale-up to process optimization and commercial manufacturing, Bora’s experienced teams support customers at every stage of the product lifecycle. For more information, visit boracdmo.com.
# # #
About Bora Pharmaceuticals
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit www.boracdmo.com.